arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

NovoCure Ltd

NVCR
$13.56 ▼ -1.04 (-7.16%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
52 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

NovoCure Ltd faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.6B
Dividend Yield —
Revenue Growth 15.7% →
Op. Margin -3.2% ↗
ROIC -2.3% ↗
FCF / Share $0.13 ↗
Trailing P/E —
Price / Book 4.5x
FCF Yield 1.0%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$193.40M
↑ +15.7% —
Net Income Profit after all expenses
$-71.14M
↓ -107.3% —
Operating Margin Operating profit as % of sales
-3.2%
↑ +44.5% 9th
FCF / Share Free cash flow per share
$0.13
↑ +1.1% —
Long-Term Debt Long-term obligations
$195.05M
↑ +100.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
10
Returns ↓
19
Financial Health ↓
40
Cash Quality
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 52 quarters